​
​

Calithera Biosciences (CALA) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

CALA Stock Forecast

Calithera Biosciences stock forecast is as follows: an average price target of $2.00 (represents a 26927.03% upside from CALA’s last price of $0.01) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.

CALA Price Target

The average price target for Calithera Biosciences (CALA) is $2.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 26927.03% upside from CALA's last price of $0.01.

CALA Analyst Ratings

Hold

According to 3 Wall Street analysts, Calithera Biosciences's rating consensus is 'Hold'. The analyst rating breakdown for CALA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Calithera Biosciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2022Leerink Partners---29.08%26927.03%
Row per page
Go to

The latest Calithera Biosciences stock forecast, released on Nov 15, 2022 by Leerink Partners company, set a price target of $2.00, which represents a -29.08% decrease from the stock price at the time of the forecast ($2.82), and a 26927.03% increase from CALA last price ($0.01).

Calithera Biosciences Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.01$0.01$0.01
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Calithera Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Calithera Biosciences's last price of $0.01. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2022SVB LeerinkMarket PerformDowngrade
Aug 29, 2022H.C. WainwrightBuyUpgrade
Apr 26, 2022Zacks Investment ResearchHoldDowngrade
Row per page
Go to

Calithera Biosciences's last stock rating was published by SVB Leerink on Nov 15, 2022. The company Downgrade its CALA rating from "null" to "Market Perform".

Calithera Biosciences Financial Forecast

Calithera Biosciences Revenue Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Sep 21Jun 21Sep 18Jun 18Mar 18Sep 17Jun 17Mar 17Sep 16Jun 16Mar 16
Revenue-----------$6.75M$3.00M-$17.07M$5.19M$7.25M$7.25M$4.19M---
Avg Forecast---------$8.51M$3.29M$9.10M$3.52M$17.12M$60.68M$4.49M$9.39M$6.29M$2.67M$108.00K$78.47K$67.79K
High Forecast---------$10.21M$3.95M$10.92M$4.23M$20.54M$72.81M$5.39M$11.27M$7.55M$3.20M$129.60K$94.17K$81.34K
Low Forecast---------$6.81M$2.63M$7.28M$2.82M$13.69M$48.54M$3.59M$7.51M$5.03M$2.13M$86.40K$62.78K$54.23K
# Analysts---------16151888148201515181915
Surprise %-----------0.74%0.85%-0.28%1.16%0.77%1.15%1.57%---

Calithera Biosciences's average Quarter revenue forecast for Jun 22 based on 15 analysts is $3.29M, with a low forecast of $2.63M, and a high forecast of $3.95M. CALA's average Quarter revenue forecast represents a -51.22% decrease compared to the company's last Quarter revenue of $6.75M (Sep 21).

Calithera Biosciences EBITDA Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Sep 21Jun 21Sep 18Jun 18Mar 18Sep 17Jun 17Mar 17Sep 16Jun 16Mar 16
# Analysts---------16151888148201515181915
EBITDA--------$-7.45M$-9.01M$-13.54M$-11.08M$-14.23M$-18.72M$-2.95M$-13.08M$-5.98M$-5.11M$-5.51M$-8.47M$-10.29M$-9.50M
Avg Forecast---------$-13.96M$-15.62M$-14.94M$-16.71M$-13.57M$-4.56M$-11.04M$-7.34M$-4.32M$-17.70M$-10.15M$-9.78M$-8.55M
High Forecast---------$-11.17M$-12.50M$-11.95M$-13.37M$-10.85M$-3.65M$-8.83M$-5.87M$-3.46M$-14.16M$-8.12M$-7.82M$-6.84M
Low Forecast---------$-16.76M$-18.75M$-17.92M$-20.05M$-16.28M$-5.48M$-13.25M$-8.81M$-5.19M$-21.24M$-12.18M$-11.73M$-10.26M
Surprise %---------0.65%0.87%0.74%0.85%1.38%0.65%1.19%0.81%1.18%0.31%0.84%1.05%1.11%

undefined analysts predict CALA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Calithera Biosciences's previous annual EBITDA (undefined) of $NaN.

Calithera Biosciences Net Income Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Sep 21Jun 21Sep 18Jun 18Mar 18Sep 17Jun 17Mar 17Sep 16Jun 16Mar 16
# Analysts---------16151888148201515181915
Net Income--------$14.12M$-10.08M$10.22M$-11.17M$-14.31M$-18.85M$-3.08M$-13.21M$-6.07M$-5.19M$-5.59M$-8.54M$-10.36M$-9.58M
Avg Forecast$-15.11M$-15.11M$-15.11M$-15.11M$-1.40M$-1.35M$-1.40M$-2.60M$-7.44M$-14.08M$-15.71M$-15.06M$-16.80M$-13.19M$-4.76M$-11.14M$-7.45M$-4.39M$-17.96M$-10.13M$-9.76M$-8.56M
High Forecast$-15.11M$-15.11M$-15.11M$-15.11M$-1.40M$-1.35M$-1.40M$-2.60M$-7.44M$-11.26M$-12.57M$-12.05M$-13.44M$-10.56M$-3.81M$-8.91M$-5.96M$-3.52M$-14.37M$-8.10M$-7.81M$-6.85M
Low Forecast$-15.11M$-15.11M$-15.11M$-15.11M$-1.40M$-1.35M$-1.40M$-2.60M$-7.44M$-16.89M$-18.85M$-18.07M$-20.16M$-15.83M$-5.71M$-13.37M$-8.94M$-5.27M$-21.55M$-12.15M$-11.71M$-10.28M
Surprise %---------1.90%0.72%-0.65%0.74%0.85%1.43%0.65%1.19%0.81%1.18%0.31%0.84%1.06%1.12%

Calithera Biosciences's average Quarter net income forecast for Mar 23 is $-2.60M, with a range of $-2.60M to $-2.60M. CALA's average Quarter net income forecast represents a -118.38% decrease compared to the company's last Quarter net income of $14.12M (Dec 22).

Calithera Biosciences SG&A Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Sep 21Jun 21Sep 18Jun 18Mar 18Sep 17Jun 17Mar 17Sep 16Jun 16Mar 16
# Analysts---------16151888148201515181915
SG&A--------$2.58M$3.08M$3.62M$6.34M$4.49M$3.09M$3.50M$3.51M$3.07M$2.85M$3.31M$2.32M$2.67M$2.59M
Avg Forecast---------$7.99M$3.78M$8.55M$4.04M$2.16M$5.41M$2.96M$3.77M$2.41M$3.06M$123.94K$90.06K$77.80K
High Forecast---------$9.59M$4.53M$10.26M$4.85M$2.59M$6.49M$3.55M$4.53M$2.89M$3.67M$148.73K$108.07K$93.35K
Low Forecast---------$6.40M$3.02M$6.84M$3.23M$1.73M$4.33M$2.37M$3.02M$1.93M$2.45M$99.16K$72.05K$62.23K
Surprise %---------0.39%0.96%0.74%1.11%1.43%0.65%1.19%0.81%1.18%1.08%18.71%29.59%33.31%

Calithera Biosciences's average Quarter SG&A projection for Mar 23 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CALA last annual SG&A of $2.58M (Dec 22).

Calithera Biosciences EPS Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Sep 21Jun 21Sep 18Jun 18Mar 18Sep 17Jun 17Mar 17Sep 16Jun 16Mar 16
# Analysts---------16151888148201515181915
EPS--------$3.05$-2.07$2.10$-3.01$-3.86$-10.36$-1.71$-7.38$-3.42$-2.94$-4.42$-8.76$-10.91$-10.42
Avg Forecast$-3.03$-3.03$-3.03$-3.03$-0.28$-0.27$-0.28$-0.52$-1.49$-1.93$1.15$1.25$1.01$-5.60$-9.90$-5.40$-5.40$-2.20$9.00$-12.80$-9.80$-8.40
High Forecast$-3.03$-3.03$-3.03$-3.03$-0.28$-0.27$-0.28$-0.52$-1.49$-1.93$1.15$1.25$1.01$-4.48$-7.92$-4.32$-4.32$-1.76$10.80$-10.24$-7.84$-6.72
Low Forecast$-3.03$-3.03$-3.03$-3.03$-0.28$-0.27$-0.28$-0.52$-1.49$-1.93$1.15$1.25$1.01$-6.72$-11.88$-6.48$-6.48$-2.64$7.20$-15.36$-11.76$-10.08
Surprise %---------2.05%1.07%1.82%-2.42%-3.82%1.85%0.17%1.37%0.63%1.34%-0.49%0.68%1.11%1.24%

According to 0 Wall Street analysts, Calithera Biosciences's projected average Quarter EPS for Mar 23 is $-0.52, with a low estimate of $-0.52 and a high estimate of $-0.52. This represents a -117.05% decrease compared to CALA previous annual EPS of $3.05 (Dec 22).

Calithera Biosciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CALACalithera Biosciences--19900.00%Hold
HEPAHepion Pharmaceuticals--10044.93%Buy
CKPTCheckpoint Therapeutics--476.37%Buy
KODKodiak Sciences--435.59%Buy
ADAPAdaptimmune Therapeutics--342.19%Buy
PDSBPDS Bio--309.09%Buy
ZURAZura Bio--241.30%Buy
AFMDAffimed--184.09%Buy
ADVMAdverum Bio--160.87%Buy
LPTXLeap Therapeutics--113.18%Buy
VSTMVerastem--111.96%Buy
MREOMereo BioPharma Group--83.42%Buy
GLMDGalmed Pharmaceuticals--78.57%Buy
ARDXArdelyx--70.90%Buy
ABEOAbeona Therapeutics--3.63%Buy

CALA Forecast FAQ

Is Calithera Biosciences a good buy?

No, according to 3 Wall Street analysts, Calithera Biosciences (CALA) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of CALA's total ratings.

What is CALA's price target?

Calithera Biosciences (CALA) average price target is $2 with a range of $2 to $2, implying a 26927.03% from its last price of $0.0074. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Calithera Biosciences stock go up soon?

According to Wall Street analysts' prediction for CALA stock, the company can go up by 26927.03% (from the last price of $0.0074 to the average price target of $2), up by 26927.03% based on the highest stock price target, and up by 26927.03% based on the lowest stock price target.

Can Calithera Biosciences stock reach $0?

CALA's average twelve months analyst stock price target of $2 supports the claim that Calithera Biosciences can reach $0 in the near future.

What are Calithera Biosciences's analysts' financial forecasts?

Calithera Biosciences's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-6.739M (high $-6.739M, low $-6.739M), average SG&A $0 (high $0, low $0), and average EPS is $-1.35 (high $-1.35, low $-1.35). CALA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-60.457M (high $-60.457M, low $-60.457M), average SG&A $0 (high $0, low $0), and average EPS is $-12.111 (high $-12.111, low $-12.111).

Did the CALA's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Sep 2021), Calithera Biosciences's revenue was $6.75M, missing the average analysts' forecast of $9.1M by -25.81%. The company's EBITDA was $-11.081M, missing the average prediction of $-14.935M by -25.81%. Calithera Biosciences's net income was $-11.172M, missing the average estimation of $-15.058M by -25.81%. The company's SG&A was $6.34M, missing the average forecast of $8.55M by -25.81%. Lastly, the company's EPS was $-3.015, missing the average prediction of $1.25 by -342.09%